FIGURE 2.

Survival curves of IPMC/invasive carcinoma patients with or without any of the oncogenic mutations. The survival was calculated by the Kaplan-Meier method, and differences in survival between the mutation groups were tested with the log-rank test. Our data suggested that patients with any oncogenic mutation may have a better survival median, although a larger study is needed in the future to obtain a significant P value. *The upper limit was a censored observation (i.e., the patient was still alive so that survival time was calculated to the date of last follow-up). †The mean survival time and its SE were underestimated because the largest observation was censored and the estimation was restricted to the largest event time. CI indicates confidence interval.